ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
November 14, 1998
Does single agent carboplatin improve survival in women with epithelial ovarian cancer?
cyclophosphamide 500mg/m2doxorubicin 50mg/m2cisplatin 50mg/m2
carboplatin AUC 5
clinician certain chemotherapy is neededepithelial ovarian cancer
carboplatin (n=760) vs combo (n=766):77% stage III or IV~80% in both arms completed 6 cyclesmore leukopenia/nausea in combo armmore thrombocytopenia with carboplatinmedian f/u: 35 mosmedian PFS: 15.5 vs 17 mos (NS)median OS: 33 vs 33 mos (NS)
Single agent carboplatin is effective and safe for women with epithelial ovarian cancer